JP2001516350A - Hivプロテアーゼインヒビター - Google Patents
HivプロテアーゼインヒビターInfo
- Publication number
- JP2001516350A JP2001516350A JP53974598A JP53974598A JP2001516350A JP 2001516350 A JP2001516350 A JP 2001516350A JP 53974598 A JP53974598 A JP 53974598A JP 53974598 A JP53974598 A JP 53974598A JP 2001516350 A JP2001516350 A JP 2001516350A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- purity
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 以下の式(9): [式中、R及びR'は、水素、置換もしくは未置換アルキル−OR1基、(C1− C6)アルキル基もしくは(C1−C6)アルキル−OH基で置換されたシクロア ルキル基、(C1−C6)アルキル基もしくは(C1−C6)アルキル−OH基で置 換された複素環基、アルキル−NR2R3基、又はアルキル−S(X)(Y)R4 基から独立に選ばれ、そして 前記において、 R1は、水素、置換もしくは未置換アルキル基、又はアシル基であり; R2及びR3は、水素、置換もしくは未置換アルキル、シクロアルキル、複 素環、及びアリール基並びにアシル及びスルホニル基から各々独立に選ばれ; R4は、水素、置換もしくは未置換アルキル、シクロアルキル、複素環、 又はアリール基であり;そして X及びYは、=O及び非存在から各々独立に選ばれる] を有する化合物、又はその医薬として許容可能なプロドラッグ、塩もしくは溶媒 和物。 2. Rが水素である請求項1の化合物、又はその医薬的に許容可能なプロド ラッグ、塩若しくは溶媒和物。 3. RおよびR’の少なくとも1つがアルキル−OR1基であり、R1が水素 である請求項1の化合物、又はその医薬的に許容可能なプロドラッグ、塩若しく は溶媒和物。 4. RおよびR’の少なくとも1つがアルキル−OR1基である、ここにお いて、当該アルキル−OR1基は、以下の基:−C(CH3)2CH2OH、−CH (CH3)CH2OH、−CH2CH2OH、−C(CH3)(CH2OH)2、−C (CH3)2−O−CH2−O−CH3、−C(CH3)2CH2−O−CH2−O−C H3、−C(CH3)2CH2−O−アシル、−C(CH3)2−S−CH2−O−C H3、−C(CH3)2CH2−S−CH2−O−CH3、−C(CH3)2−O−CH2 −S−CH3、−C(CH3)2CH2−O−CH2−S−CH3および−C(CH3 )2CH2−S−アシルである、請求項1の化合物、又はその医薬的に許容可能な プロドラッグ、塩若しくは溶媒和物。 5. 前記RおよびR’の少なくとも1つが、(C1−C6)アルキル基または (C1−C6)アルキル−OH基で置換されているシクロアルキル基であり、当該 シクロアルキル基は以下の基: から選択されるものである、請求項1の化合物、又はその医薬的に許容可能なプ ロドラッグ、塩若しくは溶媒和物。 6. 前記RおよびR’の少なくとも1つが、(C1−C6)アルキル基または (C1−C6)アルキル−OH基で置換されている複素環基であり、当該複素環基 は以下の基: [ここにおいて、R3は、水素、置換若しくは未置換のアルキル、シクロアルキ ル、複素環またはアリール基、又はアシル基若しくはスルホニル基である] から選択されるものである、請求項1の化合物、又はその医薬的に許容可能なプ ロドラッグ、塩若しくは溶媒和物。 7. 前記化合物が以下の式21:を有する、請求項1の化合物、又はその医薬的に許容可能なプロドラッグ、塩若 しくは溶媒和物。 8. R’が、(C1−C6)アルキル基または(C1−C6)アルキル−OH基 で置換されているシクロアルキル基であり、当該シクロアルキル基は以下の基: から選択されるものである、請求項2の化合物、又はその医薬的に許容可能なプ ロドラッグ、塩若しくは溶媒和物。 9. 以下の式(9b): を有する、請求項1に記載の塩。 10. (a)有効な量の請求項1に記載の化合物:および (b)前記化合物のための医薬的に許容可能な担体 を含む、医薬用組成物。 11. (a)有効な量の請求項7に記載の化合物:および (b)前記化合物のための医薬的に許容可能な担体 を含む、医薬用組成物。 12. 請求項1の化合物、又はその医薬的に許容可能なプロドラッグ、塩若し くは溶媒和物を宿主に投与することを含む、HIVプロテアーゼの投与方法。 13. 請求項7の化合物、又はその医薬的に許容可能なプロドラッグ、塩若し くは溶媒和物を宿主に投与することを含む、HIVプロテアーゼの投与方法。 14. 90%以上の精製度を有する、請求項1に記載の化合物。 15. 少なくとも95%の精製度を有する、請求項1に記載の化合物。 16. 少なくとも97%の精製度を有する、請求項1に記載の化合物。 17. 少なくとも99%の精製度を有する、請求項1に記載の化合物。 18. 90%以上の精製度を有する、請求項7に記載の化合物。 19. 少なくとも95%の精製度を有する、請求項7に記載の化合物。 20. 少なくとも97%の精製度を有する、請求項7に記載の化合物。 21. 少なくとも99%の精製度を有する、請求項7に記載の化合物。 22. 当該化合物が90%以上の精製度を有する、請求項10に記載の医薬用 組成物。 23. 当該化合物が少なくとも95%の精製度を有する、請求項10に記載の 医薬用組成物。 24. 当該化合物が少なくとも97%の精製度を有する、請求項10に記載の 医薬用組成物。 25. 当該化合物が少なくとも99%の精製度を有する、請求項10に記載の 医薬用組成物。 26. 当該化合物が90%以上の精製度を有する、請求項11に記載の医薬用 組成物。 27. 当該化合物が少なくとも95%の精製度を有する、請求項11に記載の 医薬用組成物。 28. 当該化合物が少なくとも97%の精製度を有する、請求項11に記載の 医薬用組成物。 29. 当該化合物が少なくとも99%の精製度を有する、請求項11に記載の 医薬用組成物。 30. 当該化合物が90%以上の精製度を有する、請求項12に記載の方法。 31. 当該化合物が少なくとも95%の精製度を有する、請求項12に記載の 方法。 32. 当該化合物が少なくとも97%の精製度を有する、請求項12に記載の 方法。 33. 当該化合物が少なくとも99%の精製度を有する、請求項12に記載の 方法。 34. 当該化合物が90%以上の精製度を有する、請求項13に記載の方法。 35. 当該化合物が少なくとも95%の精製度を有する、請求項13に記載の 方法。 36. 当該化合物が少なくとも97%の精製度を有する、請求項13に記載の 方法。 37. 当該化合物が少なくとも99%の精製度を有する、請求項13に記載の 方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81595197A | 1997-03-13 | 1997-03-13 | |
US08/815,951 | 1997-03-13 | ||
PCT/US1998/004735 WO1998040357A2 (en) | 1997-03-13 | 1998-03-12 | Hiv protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001516350A true JP2001516350A (ja) | 2001-09-25 |
JP2001516350A5 JP2001516350A5 (ja) | 2005-11-10 |
Family
ID=25219265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53974598A Ceased JP2001516350A (ja) | 1997-03-13 | 1998-03-12 | Hivプロテアーゼインヒビター |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP0970055A2 (ja) |
JP (1) | JP2001516350A (ja) |
KR (1) | KR100511089B1 (ja) |
CN (1) | CN1179948C (ja) |
AP (1) | AP1358A (ja) |
AR (1) | AR012556A1 (ja) |
AU (1) | AU743078B2 (ja) |
BG (1) | BG63540B1 (ja) |
BR (1) | BR9808867A (ja) |
CA (1) | CA2284163A1 (ja) |
CO (1) | CO4940496A1 (ja) |
CZ (1) | CZ296647B6 (ja) |
EA (1) | EA002378B1 (ja) |
EE (1) | EE04114B1 (ja) |
GE (1) | GEP20022764B (ja) |
HR (1) | HRP980112A2 (ja) |
HU (1) | HUP0001380A3 (ja) |
IL (2) | IL131870A0 (ja) |
IS (1) | IS5176A (ja) |
MX (1) | MXPA99008395A (ja) |
MY (1) | MY117535A (ja) |
NO (1) | NO315555B1 (ja) |
NZ (1) | NZ337706A (ja) |
OA (1) | OA11196A (ja) |
PA (1) | PA8448801A1 (ja) |
PE (1) | PE58799A1 (ja) |
PL (1) | PL192786B1 (ja) |
SA (1) | SA98181116B1 (ja) |
SK (1) | SK283636B6 (ja) |
SV (1) | SV1998000038A (ja) |
TR (1) | TR199902508T2 (ja) |
TW (1) | TW200517112A (ja) |
UA (1) | UA57772C2 (ja) |
WO (1) | WO1998040357A2 (ja) |
ZA (1) | ZA982047B (ja) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
-
1998
- 1998-03-04 HR HR08/815,951A patent/HRP980112A2/hr not_active Application Discontinuation
- 1998-03-11 ZA ZA982047A patent/ZA982047B/xx unknown
- 1998-03-12 AR ARP980101104A patent/AR012556A1/es active IP Right Grant
- 1998-03-12 CZ CZ0319199A patent/CZ296647B6/cs not_active IP Right Cessation
- 1998-03-12 TW TW094100045A patent/TW200517112A/zh unknown
- 1998-03-12 CN CNB988045389A patent/CN1179948C/zh not_active Expired - Fee Related
- 1998-03-12 MX MXPA99008395A patent/MXPA99008395A/es not_active IP Right Cessation
- 1998-03-12 MY MYPI98001071A patent/MY117535A/en unknown
- 1998-03-12 NZ NZ337706A patent/NZ337706A/en unknown
- 1998-03-12 EA EA199900823A patent/EA002378B1/ru unknown
- 1998-03-12 HU HU0001380A patent/HUP0001380A3/hu unknown
- 1998-03-12 AU AU64575/98A patent/AU743078B2/en not_active Ceased
- 1998-03-12 IL IL13187098A patent/IL131870A0/xx active IP Right Grant
- 1998-03-12 BR BR9808867-0A patent/BR9808867A/pt not_active Application Discontinuation
- 1998-03-12 EE EEP199900416A patent/EE04114B1/xx not_active IP Right Cessation
- 1998-03-12 SK SK1222-99A patent/SK283636B6/sk not_active IP Right Cessation
- 1998-03-12 WO PCT/US1998/004735 patent/WO1998040357A2/en active IP Right Grant
- 1998-03-12 EP EP98910300A patent/EP0970055A2/en not_active Withdrawn
- 1998-03-12 GE GEAP19984984A patent/GEP20022764B/en unknown
- 1998-03-12 CA CA002284163A patent/CA2284163A1/en not_active Abandoned
- 1998-03-12 JP JP53974598A patent/JP2001516350A/ja not_active Ceased
- 1998-03-12 PE PE1998000171A patent/PE58799A1/es not_active Application Discontinuation
- 1998-03-12 TR TR1999/02508T patent/TR199902508T2/xx unknown
- 1998-03-12 KR KR10-1999-7008331A patent/KR100511089B1/ko not_active IP Right Cessation
- 1998-03-12 AP APAP/P/1999/001648A patent/AP1358A/en active
- 1998-03-12 PL PL335672A patent/PL192786B1/pl not_active IP Right Cessation
- 1998-03-13 SV SV1998000038A patent/SV1998000038A/es not_active Application Discontinuation
- 1998-03-13 PA PA19988448801A patent/PA8448801A1/es unknown
- 1998-03-13 CO CO98014251A patent/CO4940496A1/es unknown
- 1998-04-21 SA SA98181116A patent/SA98181116B1/ar unknown
- 1998-12-03 UA UA99095049A patent/UA57772C2/uk unknown
-
1999
- 1999-09-10 IS IS5176A patent/IS5176A/is unknown
- 1999-09-10 NO NO19994415A patent/NO315555B1/no not_active IP Right Cessation
- 1999-09-10 IL IL131870A patent/IL131870A/en not_active IP Right Cessation
- 1999-09-13 BG BG103727A patent/BG63540B1/bg unknown
- 1999-09-13 OA OA9900207A patent/OA11196A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2146668C1 (ru) | Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидное соединение, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз | |
FI114794B (fi) | HIV-proteaasin estäjät | |
RU2130016C1 (ru) | Производные сукциноиламиногидроксиэтиламиносульфонамида, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции, способ лечения вич-инфекции | |
JPH06271534A (ja) | Aidsの処置のために有用なhiv−プロテアーゼ阻害剤 | |
JPH06234789A (ja) | Aidsの処置のために有用なhiv−プロテアーゼ阻害剤 | |
US5527829A (en) | HIV protease inhibitors | |
US20060205812A1 (en) | 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
JPH07179417A (ja) | Aidsの処置のために有用なhiv−プロテアーゼ阻害剤 | |
JP3195462B2 (ja) | エイズ治療用hivプロテアーゼ阻害剤 | |
JPH06234728A (ja) | Aidsの処置のために有用なhiv−プロテアーゼ阻害剤 | |
JPH06256277A (ja) | Aidsの処置のために有用なhiv−プロテアーゼ阻害剤 | |
JPH06234716A (ja) | Aidsの処置に有用なhiv−プロテアーゼ阻害剤 | |
JP2001516350A (ja) | Hivプロテアーゼインヒビター | |
US6001851A (en) | HIV protease inhibitors | |
PT100752A (pt) | Derivados do acido 4-amino-3-hidroxicarboxilico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050310 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080722 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090317 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090706 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090811 |